Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Predictors of high healthcare costs in elderly patients with liver cancer in end-of-life: a longitudinal population-based study

Authors: Jui-Kun Chiang, Yee-Hsin Kao

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Studies have indicated a pervasive pattern of decreasing healthcare costs during elderly patients’ last year of life. The aim of this study was to explore the predictors of high healthcare costs (HC) in elderly liver cancer patients in Taiwan during their last month of life (LML).

Methods

Costs of hospitalization, outpatient visits, aggressiveness of care, and associated costs for elderly (age ≥ 65 y) patients with liver cancer in the LML were analyzed using a national insurance database. An HC was defined as being greater than the 90th percentile (US $5093) in the LML, amounting to 38.95% of total healthcare costs.

Results

We enrolled 2121 subjects who died during 1997–2011. Mean healthcare costs per person in their LML were US $8042 ± 3477 in the HC group and US $1407 ± 1464 in the non-HC group (p < 0.001). For patients receiving aggressive end-of-life (EOL) cancer care (e.g. intensive care, cardiopulmonary resuscitation, anticancer treatment, and a high number of admission days), comorbidities of chronic kidney disease, esophageal bleeding, and receiving opioids in the LML, were significantly independent positive predictors of HCs; but admission times, comorbidities of ascites, and hypertension were negative predictors.

Conclusion

These findings could inform healthcare providers by avoiding aggressive treatments during EOL for elderly patients with liver cancer and to save on healthcare costs. Shorter admission days and more admission times in the last month of life could decrease healthcare costs.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.CrossRefPubMed
2.
3.
Lichtman SM. Guidelines for the treatment of elderly cancer patients. Cancer Control. 2003;10(6):445–53.CrossRefPubMed
4.
5.
Levinsky NG, Yu W, Ash A, Moskowitz M, Gazelle G, Saynina O, Emanuel EJ. Influence of age on Medicare expenditures and medical care in the last year of life. JAMA. 2001;286(11):1349–55.CrossRefPubMed
6.
Payne G, Laporte A, Deber R, Coyte PC. Counting backward to health care's future: using time-to-death modeling to identify changes in end-of-life morbidity and the impact of aging on health care expenditures. Milbank Q. 2007;85(2):213–57.CrossRefPubMedPubMedCentral
7.
Polder JJ, Barendregt JJ, van Oers H. Health care costs in the last year of life--the Dutch experience. Soc Sci Med. 2006;63(7):1720–31.CrossRefPubMed
8.
Tang ST, Liu TW, Shyu YI, Huang EW, Koong SL, Hsiao SC. Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001-2006. Palliat Med. 2012;26(1):80–8.CrossRefPubMed
9.
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22(2):315–21.CrossRefPubMed
10.
Barbera L, Paszat L, Qiu F. End-of-life care in lung cancer patients in Ontario: aggressiveness of care in the population and a description of hospital admissions. J Pain Symptom Manag. 2008;35(3):267–74.CrossRef
11.
Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138(8):639–43.CrossRefPubMed
12.
Dy SM, Wolff JL, Frick KD. Patient characteristics and end-of-life health care utilization among Medicare beneficiaries in 1989 and 1999. Med Care. 2007;45(10):926–30.CrossRefPubMed
13.
Sharma G, Freeman J, Zhang D, Goodwin JS. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest. 2008;133(1):72–8.CrossRefPubMed
14.
Van den Block L, Deschepper R, Drieskens K, Bauwens S, Bilsen J, Bossuyt N, Deliens L. Hospitalisations at the end of life: using a sentinel surveillance network to study hospital use and associated patient, disease and healthcare factors. BMC Health Serv Res. 2007;7(1):69.CrossRefPubMedPubMedCentral
15.
Goodlin SJ, Zhong Z, Lynn J, Fago JP, Desbiens N, Connors AF Jr, Connors AF Jr, Wenger NS, Phillips RS. Factors associated with use of cardiopulmonary resuscitation in seriously ill hospitalized adults. JAMA. 1999;282(24):2333–9.CrossRefPubMed
16.
Chalfin DB, Carlon GC. Age and utilization of intensive care unit resources of critically ill cancer patients. Crit Care Med. 1990;18(7):694–8.CrossRefPubMed
17.
Hamel MB, Davis RB, Teno JM, Knaus WA, Lynn J, Harrell F Jr, Galanos AN, Wu AW, Phillips RS. Older age, aggressiveness of care, and survival for seriously ill, hospitalized adults. SUPPORT investigators. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med. 1999;131(10):721–8.CrossRefPubMed
18.
Moorin RE, Holman CD. The cost of in-patient care in Western Australia in the last years of life: a population-based data linkage study. Health Policy. 2008;85(3):380–90.CrossRefPubMed
19.
Masuda Y, Noguchi H, Kuzuya M, Inoue A, Hirakawa Y, Iguchi A, Uemura K. Comparison of medical treatments for the dying in a hospice and a geriatric hospital in Japan. J Palliat Med. 2006;9(1):152–60.CrossRefPubMed
20.
Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003;21(6):1133–8.CrossRefPubMed
21.
Earle CC, Neville BA, Landrum MB, Souza JM, Weeks JC, Block SD, Grunfeld E, Ayanian JZ. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care. 2005;17(6):505–9.CrossRefPubMed
22.
Grunfeld E, Lethbridge L, Dewar R, Lawson B, Paszat LF, Johnston G, Burge F, McIntyre P, Earle CC. Towards using administrative databases to measure population-based indicators of quality of end-of-life care: testing the methodology. Palliat Med. 2006;20(8):769–77.CrossRefPubMedPubMedCentral
23.
Grunfeld E, Urquhart R, Mykhalovskiy E, Folkes A, Johnston G, Burge FI, Earle CC, Dent S. Toward population-based indicators of quality end-of-life care: testing stakeholder agreement. Cancer. 2008;112(10):2301–8.CrossRefPubMedPubMedCentral
24.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.CrossRefPubMed
25.
Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the project ENABLE II randomized controlled trial. JAMA. 2009;302(7):741–9.CrossRefPubMedPubMedCentral
26.
27.
Kung CM, Mo LR, Yan YH. Consumption of national health insurance medical resources by hepatocellular carcinoma patients treated using radiofrequency ablation therapy. Asia Pac J Clin Oncol. 2012;8(3):275–81.CrossRefPubMed
28.
Langton JM, Blanch B, Drew AK, Haas M, Ingham JM, Pearson SA. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. Palliat Med. 2014;28(10):1167–96.CrossRefPubMed
29.
Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630–41.CrossRefPubMed
30.
31.
Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6S):75s–80s.CrossRefPubMedPubMedCentral
32.
McCall N. Utilization and costs of Medicare services by beneficiaries in their last year of life. Med Care. 1984;22(4):329–42.CrossRefPubMed
33.
34.
35.
Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc. 2005;104(3):157–63.PubMed
36.
Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Chiou MJ. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14(2):R83.CrossRefPubMedPubMedCentral
37.
Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, Chen HJ, Pan WH, Tseng CH, Cheng SH, et al. Evidence for improved control of hypertension in Taiwan: 1993-2002. J Hypertens. 2008;26(3):600–6.CrossRefPubMed
38.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefPubMed
39.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–9.CrossRefPubMed
40.
Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258–67.CrossRefPubMed
41.
Yee TW. Quantile regression via vector generalized additive models. Stat Med. 2004;23(14):2295–315.CrossRefPubMed
42.
Carlson MD, Herrin J, Du Q, Epstein AJ, Barry CL, Morrison RS, Back AL, Bradley EH. Impact of hospice disenrollment on health care use and medicare expenditures for patients with cancer. J Clin Oncol. 2010;28(28):4371–5.CrossRefPubMedPubMedCentral
43.
Zhang B, Wright AA, Huskamp HA, Nilsson ME, Maciejewski ML, Earle CC, Block SD, Maciejewski PK, Prigerson HG. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009;169(5):480–8.CrossRefPubMedPubMedCentral
44.
Singal BM, Hedges JR, Rousseau EW, Sanders AB, Berstein E, McNamara RM, Hogan TM. Geriatric patient emergency visits. Part I: comparison of visits by geriatric and younger patients. Ann Emerg Med. 1992;21(7):802–7.CrossRefPubMed
45.
Tsukioka G, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Toyoda M, Katakai K, Kojima A, et al. Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. World J Gastroenterol. 2006;12(1):48–53.CrossRefPubMedPubMedCentral
46.
47.
48.
Hu W, Yasui Y, White J, Winget M. Aggressiveness of end-of-life care for patients with colorectal cancer in Alberta, Canada: 2006-2009. J Pain Symptom Manag. 2014;47(2):231–44.CrossRef
49.
Legler A, Bradley EH, Carlson MD. The effect of comorbidity burden on health care utilization for patients with cancer using hospice. J Palliat Med. 2011;14(6):751–6.CrossRefPubMedPubMedCentral
50.
Burge FI, Lawson BJ, Johnston GM, Grunfeld E. A population-based study of age inequalities in access to palliative care among cancer patients. Med Care. 2008;46(12):1203–11.CrossRefPubMedPubMedCentral
Metadata
Title
Predictors of high healthcare costs in elderly patients with liver cancer in end-of-life: a longitudinal population-based study
Authors
Jui-Kun Chiang
Yee-Hsin Kao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3561-5

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Case report

Retinal and vitreous metastases from hepatocholangiocarcinoma

Research article

In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line

Research article

Diagnostic value of endoscopic appearance during ductoscopy in patients with pathological nipple discharge

Study protocol

High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study

Case report

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

Research article

Predominance of girls with cancer in families with multiple childhood cancer cases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits